Teva Pharmaceutical Industries Ltd. (TEVA Quick QuoteTEVA - Free Report) reported $4.16 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 7.4%. EPS of $0.61 for the same period compares to $0.56 a year ago.

The reported revenue represents a surprise of +4.30% over the Zacks Consensus Estimate of $3.99 billion. With the consensus EPS estimate being $0.57, the EPS surprise was +7.02%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- International Markets

  : $593 million versus $630.62 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +23.8% change.

• Geographic Revenue- United States

  : $2.11 billion compared to the $1.89 billion average estimate based on four analysts. The reported number represents a change of +6% year over year.

• Geographic Revenue- United States- COPAXONE

  : $81 million versus $33.67 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +26.6% change.

• Geographic Revenue- United States- BENDEKA / TREANDA

  : $41 million versus $46.16 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -40.6% change.

• Geographic Revenue- United States- AUSTEDO

  : $407 million versus the four-analyst average estimate of $371.41 million. The reported number represents a year-over-year change of +32.1%.

• Geographic Revenue- United States- Anda

  : $373 million versus the four-analyst average estimate of $374.37 million. The reported number represents a year-over-year change of -4.9%.

• Geographic Revenue- Europe- COPAXONE

  : $53 million versus the four-analyst average estimate of $54.10 million. The reported number represents a year-over-year change of -11.7%.

• Geographic Revenue- Europe- Respiratory products

  : $57 million versus $63.64 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -13.6% change.

• Geographic Revenue- International Markets- Generic products

  : $486 million compared to the $515.16 million average estimate based on four analysts. The reported number represents a change of +23.4% year over year.

• Geographic Revenue- International Markets- COPAXONE

  : $14 million compared to the $12.66 million average estimate based on four analysts. The reported number represents a change of +40% year over year.

• Geographic Revenue- United States- AJOVY

  : $42 million versus the four-analyst average estimate of $53.78 million. The reported number represents a year-over-year change of -26.3%.

• Geographic Revenue- Europe- Generic products

  : $970 million compared to the $952.54 million average estimate based on four analysts. The reported number represents a change of +6.7% year over year.

View all Key Company Metrics for Teva Pharmaceutical Industries here>>>

Shares of Teva Pharmaceutical Industries have returned -0.9% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.